Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial.

George D. Demetri; Peter Reichardt; Yoon‐Koo Kang; Jean‐Yves Blay; Heikki Joensuu; Robert G. Maki; Piotr Rutkowski; Peter Hohenberger; Hans Gelderblom; Michael Leahy; Margaret von Mehren; Patrick Schöffski; Martin E. Blackstein; Axel Le Cesne; Giuseppe Badalamenti; Jianming Xu; Toshirou Nishida; Dirk Laurent; Iris Kuss; Paolo G. Casali; on behalf of GRID Investigators

doi:10.1200/jco.2012.30.15_suppl.lba10008

JOURNAL ARTICLE

Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial.

George D. Demetri Peter Reichardt Yoon‐Koo Kang Jean‐Yves Blay Heikki Joensuu Robert G. Maki Piotr Rutkowski Peter Hohenberger Hans Gelderblom Michael Leahy Margaret von Mehren Patrick Schöffski Martin E. Blackstein Axel Le Cesne Giuseppe Badalamenti Jianming Xu Toshirou Nishida Dirk Laurent Iris Kuss Paolo G. Casali on behalf of GRID Investigators

Year: 2012 Journal: Journal of Clinical Oncology Vol: 30 (15_suppl)Pages: LBA10008-LBA10008 Publisher: Lippincott Williams & Wilkins

DOI: 10.1200/jco.2012.30.15_suppl.lba10008

Get Full-Text PDF Get Analytical Report

Abstract

LBA10008 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Monday, June 4, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

Keywords:

Regorafenib Medicine Sunitinib GiST Imatinib Internal medicine Oncology Randomized controlled trial Stromal tumor Clinical trial Stromal cell Colorectal cancer Cancer

Metrics

Cited By

0.48

FWCI (Field Weighted Citation Impact)

Refs

0.68

Citation Normalized Percentile

Is in top 1%

Is in top 10%

Citation History

Topics

Gastrointestinal Tumor Research and Treatment

Health Sciences → Medicine → Gastroenterology

Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial.

Abstract

Metrics

Citation History

Topics

Related Documents

Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial.

Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial

Randomized Phase 3 Trial of Regorafenib in Patients (Patients) with Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST) Progressing Despite Prior Treatment with at Least Imatinib (IM) and Sunitinib (SU) : Grid Trial

Phase I Trial of Sunitinib Plus Imatinib in Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

VOYAGER: An open-label, randomised, phase III study of avapritinib vs regorafenib in patients (pts) with locally advanced (adv) metastatic or unresectable gastrointestinal stromal tumour (GIST)